Dr. Reddy's Laboratories Ltd ADR (RDY)

$14.3

-0.05

(-0.35%)▲

Market is closed - opens 8 PM, 21 Nov 2024

Performance

  • $14.24
    $14.38
    $14.30
    downward going graph

    0.42%

    Downside

    Day's Volatility :0.97%

    Upside

    0.56%

    downward going graph
  • $12.90
    $16.89
    $14.30
    downward going graph

    9.79%

    Downside

    52 Weeks Volatility :23.63%

    Upside

    15.34%

    downward going graph

Returns

PeriodDr. Reddy's Laboratories Ltd.Sector (Health Care)Index (Russel 2000)
3 Months
-15.09%
-7.6%
0.0%
6 Months
3.74%
-2.3%
0.0%
1 Year
4.73%
10.1%
0.0%
3 Years
17.71%
7.5%
-24.5%

Highlights

Market Capitalization
12.0B
Book Value
$366.54
Dividend Share
8.0
Dividend Yield
0.66%
Earnings Per Share (EPS)
0.78
PE Ratio
18.4
PEG Ratio
3.76
Wall Street Target Price
1304.449
Profit Margin
17.79%
Operating Margin TTM
22.51%
Return On Assets TTM
10.4%
Return On Equity TTM
19.27%
Revenue TTM
299.9B
Revenue Per Share TTM
60.14
Quarterly Revenue Growth YOY
16.5%
Gross Profit TTM
113.8B
EBITDA
81.8B
Diluted Eps TTM
0.78
Quarterly Earnings Growth YOY
-0.15
EPS Estimate Current Year
3.79
EPS Estimate Next Year
3.97
EPS Estimate Current Quarter
0.99
EPS Estimate Next Quarter
0.93

Analyst Recommendation

Buy
    42%Buy
    30%Hold
    27%Sell
Based on 40 Wall street analysts offering stock ratings for Dr. Reddy's Laboratories Ltd.(by analysts ranked 0 to 5 stars)
Based on 40 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
11
18
Hold
12
13
11
Sell
11
16
12

Analyst Forecast

What analysts predicted

Upside of 9022.02%

Current $14.30
Target $1,304.45

Company Financials

FY19Y/Y Change
Revenue
2.2B
↑ 8.32%
Net Income
269.6M
↑ 91.67%
Net Profit Margin
12.22%
↑ 5.32%
FY20Y/Y Change
Revenue
2.3B
↑ 13.49%
Net Income
261.4M
↑ 3.74%
Net Profit Margin
11.17%
↓ 1.05%
FY21Y/Y Change
Revenue
2.6B
↑ 8.66%
Net Income
236.7M
↓ 11.59%
Net Profit Margin
9.09%
↓ 2.08%
FY22Y/Y Change
Revenue
2.8B
↑ 13.0%
Net Income
309.2M
↑ 36.72%
Net Profit Margin
10.99%
↑ 1.9%
FY23Y/Y Change
Revenue
3.0B
↑ 14.69%
Net Income
548.0M
↑ 91.22%
Net Profit Margin
18.33%
↑ 7.34%
FY24Y/Y Change
Revenue
3.4B
↑ 13.54%
Net Income
670.6M
↑ 23.56%
Net Profit Margin
19.95%
↑ 1.62%
Q2 FY23Q/Q Change
Revenue
820.1M
↑ 7.01%
Net Income
170.7M
↑ 46.22%
Net Profit Margin
20.81%
↑ 5.58%
Q3 FY23Q/Q Change
Revenue
828.4M
↑ 2.1%
Net Income
178.2M
↑ 5.53%
Net Profit Margin
21.51%
↑ 0.7%
Q4 FY23Q/Q Change
Revenue
866.6M
↑ 4.86%
Net Income
165.6M
↓ 6.83%
Net Profit Margin
19.11%
↓ 2.4%
Q1 FY24Q/Q Change
Revenue
924.0M
↑ 6.35%
Net Income
167.6M
↑ 0.95%
Net Profit Margin
18.14%
↓ 0.97%
Q2 FY24Q/Q Change
Revenue
919.1M
↑ 0.0%
Net Income
166.8M
↑ 0.0%
Net Profit Margin
18.14%
↑ 0.0%
Q3 FY24Q/Q Change
Revenue
80.2B
↑ 4.48%
Net Income
12.6B
↓ 9.82%
Net Profit Margin
15.66%
↓ 2.48%
FY19Y/Y Change
Total Assets
3.2B
↓ 0.08%
Total Liabilities
1.2B
↓ 14.03%
FY20Y/Y Change
Total Assets
3.1B
↑ 3.02%
Total Liabilities
1.0B
↓ 9.36%
FY21Y/Y Change
Total Assets
3.6B
↑ 14.32%
Total Liabilities
1.2B
↑ 17.16%
FY22Y/Y Change
Total Assets
3.9B
↑ 11.74%
Total Liabilities
1.4B
↑ 17.25%
FY23Y/Y Change
Total Assets
3.9B
↑ 8.83%
Total Liabilities
1.1B
↓ 15.21%
FY24Y/Y Change
Total Assets
4.7B
↑ 20.03%
Total Liabilities
1.3B
↑ 18.87%
Q2 FY23Q/Q Change
Total Assets
4.1B
↑ 3.78%
Total Liabilities
673.8M
↓ 38.48%
Q3 FY23Q/Q Change
Total Assets
4.2B
↑ 3.58%
Total Liabilities
1.1B
↑ 69.67%
Q4 FY23Q/Q Change
Total Assets
4.5B
↑ 7.44%
Total Liabilities
1.3B
↑ 11.77%
Q1 FY24Q/Q Change
Total Assets
5.0B
↑ 11.39%
Total Liabilities
1.5B
↑ 14.93%
Q2 FY24Q/Q Change
Total Assets
5.0B
↑ 0.0%
Total Liabilities
1.4B
↑ 0.0%
Q3 FY24Q/Q Change
Total Assets
466.0B
↑ 12.2%
Total Liabilities
156.7B
↑ 29.84%
FY19Y/Y Change
Operating Cash Flow
411.8M
↑ 59.21%
Investing Cash Flow
-110.9M
↓ 48.08%
Financing Cash Flow
-306.0M
↑ 380.32%
FY20Y/Y Change
Operating Cash Flow
400.0M
↑ 3.96%
Investing Cash Flow
-66.0M
↓ 36.29%
Financing Cash Flow
-337.2M
↑ 17.97%
FY21Y/Y Change
Operating Cash Flow
490.2M
↑ 19.64%
Investing Cash Flow
-311.1M
↑ 360.29%
Financing Cash Flow
-4.1M
↓ 98.82%
FY22Y/Y Change
Operating Cash Flow
368.8M
↓ 21.27%
Investing Cash Flow
-346.2M
↑ 16.45%
Financing Cash Flow
-31.8M
↑ 712.75%
FY23Y/Y Change
Operating Cash Flow
715.9M
↑ 109.45%
Investing Cash Flow
-503.1M
↑ 56.79%
Financing Cash Flow
-326.6M
↑ 1009.04%
Q2 FY23Q/Q Change
Operating Cash Flow
136.9M
↓ 42.83%
Investing Cash Flow
-55.0M
↓ 89.08%
Financing Cash Flow
-18.0M
↓ 65.66%
Q3 FY23Q/Q Change
Operating Cash Flow
215.8M
↑ 59.34%
Investing Cash Flow
-153.6M
↑ 182.33%
Financing Cash Flow
-84.7M
↑ 376.69%

Technicals Summary

Sell

Neutral

Buy

Dr. Reddy's Laboratories Ltd. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
-9.19%
3.74%
4.73%
17.71%
77.42%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.76%
-12.28%
12.48%
43.36%
8.39%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-5.01%
11.27%
13.94%
27.94%
27.94%
Zoetis Inc.
Zoetis Inc.
-7.27%
1.67%
-1.71%
-21.69%
46.12%
Viatris Inc.
Viatris Inc.
13.48%
19.8%
39.98%
0.08%
-19.65%
Catalent, Inc.
Catalent, Inc.
-1.96%
7.35%
48.09%
-54.14%
14.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
18.08
18.4
3.76
3.79
0.19
0.1
0.01
366.54
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
31.77
32.88
0.28
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.58
28.73
1.69
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
33.0
33.0
2.46
5.87
0.47
0.15
0.01
11.59
Viatris Inc.
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.95
0.2
-0.11
0.0
NA
19.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
Buy
$12.1B
77.42%
18.08
17.79%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.1B
8.39%
31.77
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$42.6B
27.94%
28.58
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
46.12%
33.0
26.55%
Viatris Inc.
Viatris Inc.
Hold
$15.1B
-19.65%
224.4
-5.87%
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
14.45%
211.02
-9.34%

Insights on Dr. Reddy's Laboratories Ltd.

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 62.96B → 80.16B (in $), with an average increase of 3.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 13.92B → 12.55B (in $), with an average decrease of 9.8% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 48.1% return, outperforming this stock by 43.4%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    2.44%

  • Robeco Institutional Asset Management BV

    1.24%

  • Royal Bank of Canada

    1.23%

  • Renaissance Technologies Corp

    1.17%

  • BlackRock Inc

    1.08%

  • Aikya Investment Management Ltd

    0.83%

Corporate Announcements

  • Dr. Reddy's Laboratories Ltd. Dividends December,2024

    In the quarter ending December,2024. Dr. Reddy's Laboratories Ltd. has declared dividend of $0.48

    Read More

Company Information

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded in 1984 by Dr. K. Anji Reddy, the company provides a wide range of pharmaceuticals in India and over 25 countries worldwide. Dr. Reddy's Laboratories operates in various segments, including generic medicines, active pharmaceutical ingredients (APIs), custom pharmaceutical services, biosimilars, and differentiated formulations. The company's portfolio includes products for therapeutic areas such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's Laboratories is listed on the NYSE under the ticker symbol RDY, making its American Depositary Receipts (ADRs) available to U.S. investors. Known for its commitment to innovation, quality, and affordability, Dr. Reddy's Laboratories continues to deliver comprehensive healthcare solutions and improve the lives of patients globally. Currently Dr. Reddy's Laboratories ADR has a market cap of $13.73 Billion. It has a P.E ratio of 0.0. The shares of Dr. Reddy's Laboratories ADR are trading at $14.35 .

Organization
Dr. Reddy's Laboratories Ltd.
Employees
27048
CEO
Mr. Gunupati Venkateswara Prasad B.E.
Industry
Health Technology

FAQs